-
Sonsire Fernández,
Gemma Año,
Jorge Castaño,
Yadira Pino,
Evangelina Uribarri,
Luis A Riverón,
Bárbara Cedré,
Tania Valmaseda,
Gustavo Falero,
José L Pérez,
Juan F Infante,
Luis G García, Rosa L Solís,
Gustavo Sierra,
Arturo Talavera
[show abstract]
[hide abstract]
ABSTRACT: A vaccine candidate against cholera was developed in the form of oral tablets to avoid difficulties during application exhibited by current whole cell inactivated cholera vaccines. In this study, enteric-coated tablets were used to improve the protection of the active compound from gastric acidity. Tablets containing heat-killed whole cells of Vibrio cholerae strain C7258 as the active pharmaceutical compound was enteric-coated with the polymer Kollicoat(®) MAE-100P, which protected them efficiently from acidity when a disintegration test was carried out. Enzyme-linked immunosorbent assay (ELISA) anti-lipopolysaccharide (LPS) inhibition test and Western blot assay revealed the presence of V. cholerae antigens as LPS, mannose-sensitive haemagglutinin (MSHA) and outer membrane protein U (Omp U) in enteric-coated tablets. Immunogenicity studies (ELISA and vibriocidal test) carried out by intraduodenal administration in rabbits showed that the coating process of tablets did not affect the immunogenicity of V. cholerae-inactivated cells. In addition, no differences were observed in the immune response elicited by enteric-coated or uncoated tablets, particularly because the animal model and immunization route used did not allow discriminating between acid resistances of both tablets formulations in vivo. Clinical studies with volunteers will be required to elucidate this aspect, but the results suggest the possibility of using enteric-coated tablets as a final pharmaceutical product for a cholera vaccine.
Travel Medicine and Infectious Disease 03/2013; · 1.50 Impact Factor
-
Yulieé López,
Juan Francisco Infante,
Sergio Sifontes,
Daiyana Díaz,
Viviana Pérez,
Gemma Año,
Tamara Hernández,
Sonsire Fernández,
Jorge Luis Castaño,
Bárbara Cedré,
Reynaldo Oliva,
Luis García, Rosa L Solís,
Arturo Talavera
[show abstract]
[hide abstract]
ABSTRACT: Here we further investigate the pharmacological and toxicological properties of a cholera vaccine based on inactivated whole cells presented in either enteric coated (COA) or uncoated (U/C) tablet formulation from Vibrio cholerae C7258 strain. Tablets were dispersed in 2mL drinking water and administered orally to Sprague Dawley rats distributed in five groups (I COA7, II U/C7 immunized at 0, 7, 69days and III COA14, IV U/C14 immunized at 0, 14, 69days and V control group). Serum vibriocidal antibody response was measured after the administration of two doses with an interval of 7-14days. To further investigate the toxicological aspects a third dose was applied 10 weeks after the initial one. Animals were observed daily and water and food consumption was measured every other day. Periodic blood extractions were performed for hematology, biochemistry, and the titer of serum vibriocidal antibodies was determined. Anatomopathological analysis was performed at days 3 or 14 after the third dose. Results from clinical observations, as well as from water and food consumption and body weigh indicated no toxicity of the vaccine product. Meanwhile, no biological differences were found among different groups in hematological, hemo-chemistry, and anatomopathological studies. Moreover, enteric coated and uncoated tablets against human cholera were found to induce an immune response in rats.
Vaccine 03/2011; 29(19):3596-9. · 3.77 Impact Factor
-
Cedré Bárbara,
Fariñas Mildrey,
Callicó Adriana,
Moya Aniel,
Díaz Dayana,
Parajón,
Elina,
Valdés Yolanda,
Sifontes Sergio,
Juan Francisco Infante,
Izquierdo Luis,
García Luis,
Talavera Arturo,
Sara C. Esnard, Rosa L. Solís
[show abstract]
[hide abstract]
ABSTRACT: Pseudomonas aeruginosa constituye uno de los agentes patógenos oportunistas de mayor frecuencia de aislamiento en los diversos procesos infecciosos, por lo que es reconocido como un gran problema de salud a nivel mundial. Al no existir un fármaco de alta efectividad ni vacunas disponibles contra esta bacteria, se emplea una terapia con inmunoglobulinas polivalentes comerciales que de forma combinada con los antibióticos contribuyen a eliminar la infección, aunque los preparados disponibles en el mercado no contienen concentraciones suficientemente elevadas de anticuerpos específicos contra este microorganismo. En este trabajo se llevó a cabo la evaluación en un modelo animal de una inmunoglobulina anti-Pseudomonas aeruginosa para uso terapéutico mediante un ensayo de reto con una cepa virulenta. Se evaluó dosis y vía de administración de la misma, así como el valor profiláctico o terapéutico de los anticuerpos. Esta gammaglobulina resultó ser protectora en animales mostrando una sobreviviencia cercana a un 75% en comparación con el grupo control no protegido y además se logra eliminar el estado de portador en los individuos infectados.
VacciMonitor. 01/2007;
-
Caridad Zayas,
Gustavo Bracho,
Miriam Lastre,
Domingo González,
Danay Gil,
Reinaldo Acevedo,
Judith del Campo,
Carlos Taboada, Rosa L Solís,
Ramón Barberá,
Oliver Pérez
[show abstract]
[hide abstract]
ABSTRACT: Cochleate are highly stable structures with promising immunological features. Cochleate structures are usually obtaining from commercial lipids. Proteoliposome derived Cochleate are derived from an outer membrane vesicles of Neisseria meningitidis B. Previously, we obtained Cochleates using dialysis procedures. In order to increase the production process, we used a crossflow system (CFS) that allows easy scale up to obtain large batches in an aseptic environment. The raw material and solutions used in the production process are already approved for human application. This work demonstrates that CFS is very efficient process to obtain Cochleate structures with a yield of more than 80% and the immunogenicity comparable to that obtained by dialysis membrane.
Vaccine 05/2006; 24 Suppl 2:S2-94-5. · 3.77 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Cochleate structures (CS) consist in a highly stable lipid structures that have been reported to be a good antigen delivery system. The incorporation of pathogen associated molecular pattern (PAMP) from bacterial membranes into CS became in a promising approach to develop adjuvants, particularly mucosal adjuvants. Therefore, we prepare CS from proteoliposome (PL) obtained from Neisseria meningitidis B (PLCS) and evaluated it for its capability to stimulate the immune system as well as the adjuvant activity. The ability of PLCS to induce Thl polarization was also explored. The results and the easy capability for new antigen incorporation on CS support its use as adjuvant for immunization with a large variety of pathogen derived antigens and different routes of immunization.
Vaccine 05/2006; 24 Suppl 2:S2-30-1. · 3.77 Impact Factor
-
Oliver Pérez,
Gustavo Bracho,
Miriam Lastre,
Caridad Zayas,
Domingo González,
Danay Gil,
Judith del Campo,
Reinaldo Acevedo,
Carlos Taboada,
Tamara Rodríguez,
María E Fajardo,
Gustavo Sierra,
Concepción Campa,
Nestor Mora,
Ramón Barberá, Rosa L Solís
[show abstract]
[hide abstract]
ABSTRACT: Proteoliposome (PL) has been recently used as a protective intramuscular (i.m.) anti-meningococcal BC vaccine. It induces a preferential Th 1 type of immune response. Nevertheless, mucosal protection is mainly mediated by IgA antibody response, which is not usually induced by i.m. vaccination route. IgA antibody production needs the stimulation of Th3 subpopulation, which is also related to the induction of small dose tolerance. We hypothesized that PL-derived Cochleate can induce a specific mucosal IgA and systemic IgG antibody responses. We could show that mice immunized with two or three intranasal doses of PL-derived Cochleate developed significantly increased levels of local anti PL IgA and systemic IgG antibody responses. Thus, our results suggest that PL-derived Cochleate can be used as a promising immunomodulator and delivery system for the development of mucosal, particularly nasal vaccines.
Vaccine 05/2006; 24 Suppl 2:S2-52-3. · 3.77 Impact Factor
-
Nesty Olivares,
Annette León,
Yamilé López,
Alina Puig,
Armando Cádiz,
Gustavo Falero,
Máximo Martínez,
Marie E Sarmiento,
Mildrey Fariñas,
Juan F Infante,
Gustavo Sierra, Rosa L Solís,
Armando Acosta
[show abstract]
[hide abstract]
ABSTRACT: The effect of the administration of a commercial preparation of human gamma globulins has been evaluated in a mouse model of intranasal infection with BCG. First, we demonstrated the passage of specific antibodies to saliva and lung lavage following the intranasal or intraperitoneal administration to mice of human gamma globulins. This treatment of mice inhibited BCG colonization of the lungs (p < 0.01). A similar inhibitory effect was observed after infection of mice with gamma globulin opsonized BCG organisms (p < 0.01). These results are relevant for the development of new strategies for the control and treatment of tuberculosis.
Tuberculosis 86(3-4):268-72. · 3.47 Impact Factor
